Welcome to our dedicated page for Biodexa Pharmaceuticals plc news (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals plc stock.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company pioneering targeted drug delivery solutions for conditions with unmet medical needs. This dedicated news hub provides investors and researchers with timely updates on clinical trials, regulatory milestones, and strategic developments.
Access consolidated information on Biodexa's innovative pipeline including eRapa for familial adenomatous polyposis, Tolimidone for diabetes management, and MTX110 for aggressive brain cancers. Track advancements in the company's proprietary drug delivery platforms designed to enhance therapeutic efficacy through improved bioavailability and targeted distribution.
Our continuously updated resource features official press releases, partnership announcements, and financial disclosures. Stay informed about Biodexa's strategy of repurposing established molecules through advanced formulation technologies to reduce clinical development risks.
Bookmark this page for direct access to primary source materials about Biodexa's progress in oncology, metabolic disorders, and rare diseases. Check regularly for updates on trial results, regulatory submissions, and corporate developments that shape the company's trajectory in biopharmaceutical innovation.
Biodexa Pharmaceuticals (NASDAQ:BDRX) reported promising results from a Phase 2 trial of eRapa, a drug aimed at treating familial adenomatous polyposis (FAP). This genetic condition, which almost always leads to colorectal cancer if untreated, currently has no non-surgical treatments. The trial included 30 adults and showed a statistically significant 24% reduction in polyp burden after six months, with an 83% non-progression rate. The Cancer Prevention Research Institute of Texas (CPRIT) awarded a $17 million grant for a Phase 3 study, requiring a $8.5 million match, of which Biodexa has secured $7 million. The 12-month results of the Phase 2 trial will be presented at the InSIGHT conference in Barcelona on June 19-22, and a Phase 3 trial is planned for early 2025.
Biodexa Pharmaceuticals announced $7 million in gross proceeds from the exercise of Series E and F warrants. The funds will cover the first year of obligations for the eRapa Phase 3 trial in Familial Adenomatous Polyposis (FAP) and unlock $17 million in non-dilutive grant funding. The warrant exercises involved 4,358,322 American Depositary Shares (ADSs) at a reduced price of $1.50 per ADS. The company will issue new unregistered warrants to purchase 6,537,483 ADSs at $2.50 per ADS. These proceeds will advance clinical stage assets and support working capital. Significant data for eRapa in FAP showed a statistically significant decrease in polyp burden and an 83% non-progression rate at six months.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced positive Phase 2 clinical trial results of its new drug eRapa for treating Familial Adenomatous Polyposis (FAP). The trial, involving 30 adult patients at seven U.S. centers, showed an 83% non-progression rate at six months and a statistically significant 24% reduction in overall mean polyp burden (p=0.04). The study was partially funded by a $20M grant from the Cancer Prevention and Research Institute of Texas. The results will be presented at the 2024 Digestive Disease Week annual meeting. The drug appeared safe and well-tolerated, with 97% of patients remaining on treatment at six months.
Biodexa Pharmaceuticals (NASDAQ: BDRX) has posted its Annual Report for the year ending December 31, 2023, and issued a Notice of Annual General Meeting (AGM) to shareholders. The AGM will be held on June 13, 2024, at the company's offices in Cardiff. Shareholders are provided with information on how to vote by proxy. The company's issued share capital consists of 2,238,225,722 Ordinary Shares with voting rights. Biodexa does not hold shares in treasury, and each American Depositary Share comprises 400 Ordinary Shares.
Biodexa Pharmaceuticals (NASDAQ:BDRX) is set to start phase 3 clinical trials for eRapa to combat Familial Adenomatous Polyposis (FAP), a precancerous condition leading to colorectal cancer. The acquisition of eRapa, supported by a $17 million grant, marks Biodexa's second portfolio expansion in six months, strengthening its position in the biopharmaceutical industry. The potentially life-changing eRapa could be the first drug to treat FAP, offering hope to patients facing invasive surgeries and lifelong complications.
Biodexa Pharmaceuticals PLC, through its licensor Emtora Biosciences, will present the Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the 2024 Digestive Disease Week Annual Meeting. The presentation is set for May 18-21, 2024, in Washington DC. Biodexa recently acquired exclusive rights to eRapa, showcasing its commitment to developing innovative treatments for unmet medical needs.
FAQ
What is the current stock price of Biodexa Pharmaceuticals plc (BDRX)?
What is the market cap of Biodexa Pharmaceuticals plc (BDRX)?
